This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

Antibody Engineering & Therapeutics US
December 15 - 18, 2024
Marriott Marquis San DiegoLive In-Person Event: December 15 - 18, 2024

Jyothsna Visweswaraiah, PhD
Director, Biotherapeutics Drug Creation at Seismic Therapeutic


Dr. Jyothsna Visweswaraiah is an accomplished leader with extensive experience in drug development, having successfully advanced new therapies into clinical trials. Currently, she serves as the head of the Biotherapeutics group under the Drug Creation Department at Seismic Therapeutic.

Previously, Jyothsna was the head of antibody discovery and engineering at a Flagship Pioneering New co, where she led the development of a modular, multi-specific biologics platform to address complex biological challenges. Prior to this, she worked at Pandion Therapeutics, where she developed novel therapeutics for autoimmune diseases, leading programs including a successful IL-2 mutein program (for TReg expansion) from inception to first-in-human trials in under two years.

Jyothsna has trained at Harvard Medical School and the National Institutes of Health. She is an advocate for women in science and workplace inclusiveness, and mentors students interested in STEM careers and early-career women scientists. In recognition of her efforts, she was invited to join the advisory board and subsequently the board of directors of WESTorg, a community that provides women in science and technology with the inspiration, knowledge, and connections to reach their full potential. Jyothsna also volunteers with The Antibody Society as a part of the communications and membership committee.

Agenda Sessions

  • Dual-cell Bidirectional (DcB) Antibodies for Targeting Multiple Inhibitory Pathways for Controlling Inflammation